Acorda Therapeutics (ACOR +7.4%) trades up after its Q3 earnings beat estimates this morning....

|About: Acorda Therapeutics, Inc. (ACOR)|By:, SA News Editor

Acorda Therapeutics (ACOR +7.4%) trades up after its Q3 earnings beat estimates this morning. Sales of lead product Ampyra came in at $69M for the period, up 5% Y/Y, and above the Consensus expectations of $68M. The company also said that it is reaffirming its 2012 Ampyra net sales guidance of $255M - $275M.